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Introduction: Paroxetine, gabapentine and olanzapine are drugs used in mental disorders (e.g. 
epilepsy, aggressive behaviour, schizophrenic and bipolar dysfunctions), very often in 
prolonged, life-long, therapies. However, since these drugs are poorly water soluble and exist in 
several polymorphic forms, they exhibit remarkably different clinical outcomes (1). 
Amorphization is a strategy used over the last decade to enhance the water solubility of drugs 
(2), in contrast with previous strategies of crystal engineering. Amorphization can be achieved 
by reducing the particle size to the nanometric scale, using a milling ball technique (3). The goal 
of the present work is to obtain amorphous particles of the three drugs, using different milling 
conditions, and characterize (size and morphology) these particles by hot-stage microscopy and 
laser diffraction. 
Materials and Methods: Particles were obtained using a planetary ball mill (PM 100 CM, 
Retsch) operated in different conditions (time of milling, speed of the mill, size of the spheres 
used, dry or wet milling, presence or absence of Tween 60, as a surfactant). The size and 
shape of olanzapine, paroxetine and gabapentin particles were determined by microscopy 
(Olympus BX51, Japan, fitted with polarized light and a heating stage, Linkam THMS350V, UK) 
and laser diffractometry (Mastersizer 2000, Malvern, equipped with a Hydro 2000S sample 
dispersion unit). Particle size and size distribution were determined using the manufacturers’ 
(Olympus and Malvern) software. 
Results: The size of particles (laser diffractometry and microscopic analyses) decreased with 
the milling time for both dry and wet milling, for all drugs. For olanzapine, dry milling seemed to 
be more effective in size reduction than wet (water) milling for all the rotations tested (100, 250, 
400, 650rpm). Milling (dry and wet) of the other drugs, for 10 min, either at 400 or 650 rpm, 
resulted in a particle size reduction to almost 50%. When wet milling was considered the most 
effective amount of water was 2,5mL for all speeds (10min milling). Results have also shown 
that the most effective diameter of the milling spheres was 3mm diameter, for both dry and wet 
milling. Microscopy has shown for paroxetine and gabapentin a reduction in the size of particles 
of 40 and 16%, respectively (dry milling for 30 or 60min, at 650rpm).  
Discussion and Conclusions: The minimum size achieved was on the micrometer scale and 
the milled particles of all the drugs remained in the crystalline state. In fact, the longest milling 
time tested (60min) and/or the highest mill speed considered (650rpm) in these preliminary 
studies were not sufficient to attain particles in the nanometer range, nor the amorphous state 
for the three drugs. In future studies, different processing conditions, such as higher speed and 
milling time, should thus be considered. 
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